AbCellera Shares T-Cell Engager Data at SITC 2024

AbCellera, a prominent biotechnology firm based in Vancouver, British Columbia, has recently unveiled new data on its T-cell engager (TCE) platform. This information will be presented in a poster format at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held at the George R. Brown Convention Center in Houston, Texas.

The TCE platform developed by AbCellera is designed to address significant challenges in the development of T-cell engagers. These challenges include creating CD3-binding antibodies to enhance the therapeutic window by producing TCEs with strong tumor-cell killing abilities while maintaining optimal cytokine release. Additionally, the platform includes molecules that boost efficacy for solid tumors by promoting T-cell activation and proliferation through the costimulation of CD28 and 4-1BB.

In its presentation, AbCellera highlights the application of its platform to two specific TCE programs. The preclinical characterization of TCEs targeting solid tumor markers B7-H4 and PSMA shows promising results. These TCEs demonstrate tumor-cell killing and cytokine release profiles that are distinct from existing clinical benchmarks, suggesting potential improvements in cancer treatment.

The CD3 T-cell engagers hold significant promise in cancer therapy by guiding the immune system to locate and destroy cancer cells. They achieve this by binding simultaneously to tumor targets and the CD3 protein on T cells, which are crucial for killing cancer cells. However, developing these T-cell engagers has been fraught with challenges related to efficacy and safety. AbCellera's platform aims to overcome these obstacles by incorporating novel CD3-binding antibodies, costimulatory elements to enhance treatment effectiveness for hard-to-treat cancers, and advanced discovery capabilities to broaden the range of T-cell engagers for complex tumor targets. The company is leveraging this platform to unlock the full potential of TCEs, aiming to deliver new cancer treatments to patients.

AbCellera Biologics Inc. is a company focused on discovering and developing antibody medicines across various therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company's engine integrates cutting-edge technology, data science, infrastructure, and interdisciplinary teams to tackle the most challenging problems in antibody discovery. AbCellera's mission includes advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development initiatives with partners. For more information about the company and its initiatives, please visit their website at www.abcellera.com.

Overall, AbCellera's new data presentation at the SITC Annual Meeting showcases their ongoing efforts to innovate and improve cancer treatment through their advanced T-cell engager platform. With promising preclinical results, AbCellera continues to push the boundaries of medical science, aiming to bring effective new treatments to cancer patients worldwide.